Goldie S J, Kiernan-Tridle L, Torres C, Gorban-Brennan N, Dunne D, Kliger A S, Finkelstein F O
Department of Internal Medicine, Hospital of Saint Raphael, Yale University School of Medicine, New Haven, CT 06511, USA.
Am J Kidney Dis. 1996 Jul;28(1):86-91. doi: 10.1016/s0272-6386(96)90135-3.
Fungal peritonitis (FP) is a rare but serious complication of chronic peritoneal dialysis (CPD) therapy and is associated with high morbidity and CPD drop-out. Risk factors and management of FP remain controversial. We reviewed our experience with FP in an attempt to identify risk factors and to examine outcome in relation to treatment strategies. Between March 1984 and August 1994, 704 patients were maintained on CPD therapy in our unit. A total of 1,712 episodes of peritonitis were identified among these patients. Fungal peritonitis accounted for 55 (3.2%) of these episodes. The patients on CPD therapy who developed FP were similar to those who did not develop FP with regard to age, gender, underlying etiology for end-stage renal disease, and comorbid disease. Prior antibiotic use was noted in 87.3% of episodes of FP. The peritonitis rate in the patients who developed FP was one episode every 5.1 months compared with one episode every 9.9 patient-months in the CPD patients who did not develop this infection. Candida sp caused 74.5% of the episodes of FP. All patients were treated with antifungal drugs. In 85.5% of infections the Tenckhoff catheter was removed within 1 week of the diagnosis of FP; 31.9% of the patients who had the Tenckhoff catheter removed did not have the catheter replaced because of death or transfer to hemodialysis. In the patients who developed FP, 68.1% had the Tenckhoff catheter replaced; of these patients, 90.6% and 59.4% were on CPD therapy 1 and 6 months after catheter replacement, respectively. We conclude that risk factors identified in our population include peritonitis rate and prior antibiotic use. Fungal peritonitis is rare in our CPD population, and although it leads to significant CPD drop-out, it can be managed in many patients with antifungal therapy, early catheter removal, and temporary hemodialysis. Of the catheters replaced between 2 and 8 weeks after the diagnosis of FP, 91% functioned successfully, allowing continuation of CPD.
真菌性腹膜炎(FP)是慢性腹膜透析(CPD)治疗中一种罕见但严重的并发症,与高发病率和CPD治疗中断相关。FP的危险因素和管理仍存在争议。我们回顾了我们在FP方面的经验,试图确定危险因素并研究与治疗策略相关的结果。1984年3月至1994年8月期间,我们单位有704例患者接受CPD治疗。在这些患者中总共确定了1712次腹膜炎发作。真菌性腹膜炎占这些发作的55次(3.2%)。发生FP的CPD治疗患者在年龄、性别、终末期肾病的潜在病因和合并症方面与未发生FP的患者相似。87.3%的FP发作病例有先前使用抗生素的情况。发生FP的患者腹膜炎发生率为每5.1个月发作一次,而未发生这种感染的CPD患者为每9.9患者月发作一次。念珠菌属导致了74.5%的FP发作。所有患者均接受抗真菌药物治疗。在85.5%的感染中,在诊断FP后1周内拔除了Tenckhoff导管;因死亡或转为血液透析而拔除Tenckhoff导管的患者中,31.9%未更换导管。在发生FP的患者中,68.1%更换了Tenckhoff导管;在这些患者中,分别有90.6%和59.4%在导管更换后1个月和6个月继续接受CPD治疗。我们得出结论,在我们的人群中确定的危险因素包括腹膜炎发生率和先前使用抗生素的情况。真菌性腹膜炎在我们的CPD人群中很少见,虽然它会导致显著的CPD治疗中断,但许多患者可以通过抗真菌治疗、早期导管拔除和临时血液透析进行管理。在诊断FP后2至8周内更换的导管中,91%功能成功,从而允许继续进行CPD治疗。